Given the potential clinical benefit for addition of ficlatuzumab to cytotoxic therapy, further evaluation of HGF/c-Met pathway inhibitors may be warranted in patients with pancreatic cancer, although alternate cytotoxic backbones that do not induce additive peripheral edema may be preferable. This evidence concerns the gene MET and familial pancreatic carcinoma.